The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The company will review FDA's response and decide on appropriate next steps soon.
Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
The centralized marketing authorization granted by the EC is valid in all EU Member
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.
The partnership is a significant step in delivering advanced cancer therapies to patients.
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
Subscribe To Our Newsletter & Stay Updated
